BioSpace News Archive

HOOKIPA Pharma Inc. today announced that the company will participate in the virtual SVB Securities Global Biopharma Conference, February 14 - 16, 2023.

OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering 2022 fourth quarter financial results and certain business developments for 5:00 pm ET (2:00 pm PT) on Tuesday, February 14, 2023.

Axsome Therapeutics, Inc. today announced that Herriot Tabuteau, MD, Axsome’s Chief Executive Officer, will participate in a fireside chat at the SVB Securities Global Biopharma Conference on Wednesday, Feb. 15, 2023, at 8:40 a.m. Eastern Time.

Anavex Life Sciences Corp. today reported financial results for its fiscal quarter ended December 31, 2022.

Clearside Biomedical, Inc. announced today that data from the Company’s OASIS Phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) will be presented at the following medical meetings in February 2023.

First Wave BioPharma, Inc. today announced that on February 6, 2023, the Company received formal notice from the Nasdaq Hearing Panel (the “Panel”) indicating that First Wave BioPharma has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) and advised that the Panel’s oversight process of the Company is now closed.

Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced its financial results and operational highlights for the quarter ended December 31, 2022, and that the Phase 1/2 ABILITY study of MDNA11 has advanced to a sixth dose escalation cohort.

Nykode Therapeutics ASA today announced that its Chief Executive Officer, Michael Engsig, will present and host 1x1 meetings at the SVB Securities Global Biopharma Conference on Thursday, February 16, 2023, at 8:00 a.m. ET / 2:00 p.m. CET.

XORTX Therapeutics Inc. is pleased to provide a summary of Company’s progress in 2022 and milestones planned for 2023.

Today, Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced that an Arch scientist at the University of Calgary was awarded a Canadian Institute of Health Resources (CIHR) Project Grant worth $1,109,250 to further study the role of dipeptidase-1 (DPEP-1) in renal inflammation and chronic kidney disease (CKD).